JP5405303B2 - 置換されたスルホンアミド誘導体 - Google Patents

置換されたスルホンアミド誘導体 Download PDF

Info

Publication number
JP5405303B2
JP5405303B2 JP2009529606A JP2009529606A JP5405303B2 JP 5405303 B2 JP5405303 B2 JP 5405303B2 JP 2009529606 A JP2009529606 A JP 2009529606A JP 2009529606 A JP2009529606 A JP 2009529606A JP 5405303 B2 JP5405303 B2 JP 5405303B2
Authority
JP
Japan
Prior art keywords
group
alkyl
substituted
mmol
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009529606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010504930A5 (enExample
JP2010504930A (ja
Inventor
オーバーベルシュ・シュテファン
シュンク・シュテファン
ライヒ・メラニー
ヘース・ザビーネ
ヨストック・ルート
エンゲルス・ミヒャエル
クレス・アヒム
クリストフ・トーマス
シーネ・クラウス
ゲルマン・ティーノ
ビスターフェルト・エドヴァルト
Original Assignee
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング filed Critical グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング
Publication of JP2010504930A publication Critical patent/JP2010504930A/ja
Publication of JP2010504930A5 publication Critical patent/JP2010504930A5/ja
Application granted granted Critical
Publication of JP5405303B2 publication Critical patent/JP5405303B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2009529606A 2006-09-29 2007-09-27 置換されたスルホンアミド誘導体 Expired - Fee Related JP5405303B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006046743.4 2006-09-29
DE102006046743 2006-09-29
PCT/EP2007/008417 WO2008040492A1 (de) 2006-09-29 2007-09-27 Substituierte sulfonamid-derivate

Publications (3)

Publication Number Publication Date
JP2010504930A JP2010504930A (ja) 2010-02-18
JP2010504930A5 JP2010504930A5 (enExample) 2013-10-10
JP5405303B2 true JP5405303B2 (ja) 2014-02-05

Family

ID=38740241

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009529606A Expired - Fee Related JP5405303B2 (ja) 2006-09-29 2007-09-27 置換されたスルホンアミド誘導体

Country Status (23)

Country Link
US (3) US20080153843A1 (enExample)
EP (2) EP2383267A1 (enExample)
JP (1) JP5405303B2 (enExample)
KR (1) KR20090079914A (enExample)
CN (1) CN101553481A (enExample)
AU (1) AU2007304475B2 (enExample)
BR (1) BRPI0714764A2 (enExample)
CA (1) CA2664810A1 (enExample)
CO (1) CO6170358A2 (enExample)
CY (1) CY1114669T1 (enExample)
DK (1) DK2066659T3 (enExample)
ES (1) ES2436020T3 (enExample)
HR (1) HRP20130958T1 (enExample)
IL (1) IL197814A0 (enExample)
MX (1) MX2009003382A (enExample)
NO (1) NO20091299L (enExample)
NZ (1) NZ575566A (enExample)
PL (1) PL2066659T3 (enExample)
PT (1) PT2066659E (enExample)
RU (1) RU2462464C2 (enExample)
SI (1) SI2066659T1 (enExample)
WO (1) WO2008040492A1 (enExample)
ZA (1) ZA200902915B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007020493A1 (de) * 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Amid-Derivate
JP2011509962A (ja) * 2008-01-17 2011-03-31 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換スルホンアミド誘導体
RU2503674C2 (ru) * 2008-04-08 2014-01-10 Грюненталь Гмбх Замещенные производные сульфонамида
TW201022267A (en) 2008-10-23 2010-06-16 Gruenenthal Gmbh Substituierte pyrimidin-und triazin-derivate
AU2009309988A1 (en) 2008-10-29 2010-05-06 Grunenthal Gmbh Substituted spiroamines
TW201020247A (en) 2008-11-06 2010-06-01 Gruenenthal Gmbh Substituierte disulfonamide
TW201031665A (en) 2009-02-04 2010-09-01 Gruenenthal Gmbh Substituted indole-compound
TW201030007A (en) 2009-02-06 2010-08-16 Gruenenthal Gmbh Substituted spiro-amides as b1r modulators
TW201035102A (en) 2009-03-04 2010-10-01 Gruenethal Gmbh Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
TW201038572A (en) 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
EP2440542B1 (en) 2009-06-08 2013-12-18 Grünenthal GmbH Substituted benzimidazoles, benzonthiazoles and benzoxazoles
AU2011236933A1 (en) 2010-04-05 2013-05-02 Shionogi & Co., Ltd. Cephem compound having catechol group
WO2012028331A1 (en) 2010-09-03 2012-03-08 Grünenthal GmbH Substituted tetrahydropyrrolopyrazine derivatives
TW201217312A (en) 2010-09-22 2012-05-01 Gruenenthal Gmbh Substituted benzamide compounds
CN106748627A (zh) * 2016-11-14 2017-05-31 苏州市罗森助剂有限公司 一种一锅法制备3,5‑二甲基溴苯的方法
CA2965062A1 (en) * 2017-04-25 2018-10-25 Nova Chemicals Corporation Complex comprising odh unit with integrated oxygen separation module
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
CN109810031B (zh) * 2017-11-21 2023-10-17 乳源瑶族自治县东阳光生物科技有限公司 非罗考昔中间体的制备方法
WO2023028056A1 (en) 2021-08-24 2023-03-02 Genentech, Inc. 3-amino piperidyl sodium channel inhibitors
CN116253667B (zh) * 2022-12-27 2024-08-30 煤炭科学研究总院有限公司 一种聚集诱导发光材料及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59712118D1 (de) * 1996-10-14 2005-01-20 Aventis Pharma Gmbh Verwendung von nicht-peptidischen Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung und Prävention der Alzheimerischen Krankheit
FR2790260B1 (fr) * 1999-02-26 2001-05-04 Fournier Ind & Sante Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US20040171614A1 (en) * 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors
US7256186B2 (en) * 2002-02-06 2007-08-14 Schering Corporation Gamma secretase inhibitors
TW200302717A (en) * 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
MXPA05010883A (es) * 2003-04-10 2006-01-23 Amgen Inc Derivados de amina ciclica y su uso en el tratamiento de trastornos inflamatorios relacionados mediados por bradiquinina.
EP1664010A1 (en) * 2003-08-29 2006-06-07 Vernalis (R&D) Limited Sulfonamides antagonising n-type calcium channels
US20050212663A1 (en) * 2004-03-23 2005-09-29 Michihiro Matsumoto Equipment installation-place setting system, equipment control apparatus, electrical equipment, equipment installation-place setting method and computer-readable record medium storing equipment installation-place setting program
WO2005113542A2 (en) * 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
DE102005013967A1 (de) * 2004-11-05 2006-10-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20060217362A1 (en) 2004-12-29 2006-09-28 Tung Jay S Novel compounds useful for bradykinin B1 receptor antagonism
ATE498358T1 (de) 2005-06-29 2011-03-15 Compumedics Ltd Sensoranordnung mit leitfähiger brücke
WO2007101007A2 (en) * 2006-02-23 2007-09-07 Neurogen Corporation Aryl sulfonyl heterocycles
TW200801513A (en) * 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
WO2008024692A1 (en) * 2006-08-23 2008-02-28 Neurogen Corporation N-oxide aryl sulfones and sulfoxides
DE102007020493A1 (de) * 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Amid-Derivate
JP2011509962A (ja) * 2008-01-17 2011-03-31 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換スルホンアミド誘導体
TW200940528A (en) * 2008-03-05 2009-10-01 Gruenenthal Gmbh Substituted sulfonamide derivatives
US8124624B2 (en) * 2008-04-08 2012-02-28 Gruenenthal Gmbh Substituted sulfonamide compounds
RU2503674C2 (ru) * 2008-04-08 2014-01-10 Грюненталь Гмбх Замещенные производные сульфонамида
TW200944530A (en) * 2008-04-09 2009-11-01 Gruenenthal Chemie Substituted sulfonamide derivatives

Also Published As

Publication number Publication date
RU2009115960A (ru) 2010-11-10
HK1132266A1 (en) 2010-02-19
AU2007304475A1 (en) 2008-04-10
US8435978B2 (en) 2013-05-07
CN101553481A (zh) 2009-10-07
EP2066659B1 (de) 2013-08-28
US20100317644A1 (en) 2010-12-16
HRP20130958T1 (hr) 2013-11-22
CA2664810A1 (en) 2008-04-10
MX2009003382A (es) 2009-04-08
SI2066659T1 (sl) 2013-10-30
ES2436020T3 (es) 2013-12-26
PL2066659T3 (pl) 2014-01-31
WO2008040492A1 (de) 2008-04-10
EP2383267A1 (de) 2011-11-02
EP2066659A1 (de) 2009-06-10
NO20091299L (no) 2009-04-29
JP2010504930A (ja) 2010-02-18
KR20090079914A (ko) 2009-07-22
PT2066659E (pt) 2013-11-07
RU2462464C2 (ru) 2012-09-27
CO6170358A2 (es) 2010-06-18
US20100324009A1 (en) 2010-12-23
AU2007304475B2 (en) 2012-07-26
US20080153843A1 (en) 2008-06-26
NZ575566A (en) 2011-05-27
DK2066659T3 (da) 2013-12-09
BRPI0714764A2 (pt) 2014-12-30
CY1114669T1 (el) 2016-10-05
ZA200902915B (en) 2010-02-24
IL197814A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
JP2010504930A (ja) 置換されたスルホンアミド誘導体
JP5406722B2 (ja) ブラジキニン1受容体モジュレータとしての置換されたスルホンアミド誘導体
JP6993357B2 (ja) Apjアゴニストとしての6-ヒドロキシ-5-(フェニル/ヘテロアリールスルホニル)ピリミジン-4(1h)-オン
JP6837482B2 (ja) Apjアゴニストとしての2,4−ジヒドロキシ−ニコチンアミド
JP6948322B2 (ja) Apj受容体のapjアゴニストとしてのヘテロアリールヒドロキシピリミジノン
JP2012519196A (ja) スルホニル化されたテトラヒドロアゾロピラジンおよびその医薬としての使用
KR20130032863A (ko) 조혈 성장 인자 모방체 소분자 화합물 및 이의 용도
WO2006113140A2 (en) Novel compounds useful for bradykinin b1 receptor antagonism
JP2017500362A (ja) ピラゾロ[1,5−a]ピリジン誘導体およびその使用方法
JP2013507416A (ja) Mdm2−p53相互作用の阻害剤として新規なn−置換ピロリジン
KR20070026357A (ko) 인돌 유도체, 및 키나제 억제제, 특히 ikk2억제제로서의 그의 용도
NZ584573A (en) Heterocyclic compound and pharmaceutical composition thereof
JP2012529448A (ja) 置換されたベンズイミダゾール類、ベンゾチアゾール類およびベンゾオキサゾール類
CN103339108A (zh) 蛋白酶激活受体2(par2)拮抗剂
CN101208311B (zh) 作为mGluR5拮抗剂的吡嗪-2-甲酰胺衍生物
JP5069119B2 (ja) 血管内皮成長因子(vegf)受容体キナーゼインヒビターとしてのニコチンアミドピリジンウレア
JP2012516860A (ja) ブラジキニンレセプター1モジュレータとしての置換されたインドール化合物
CA2417059A1 (en) 3-substituted isoquinolin-1-yl derivatives
JP2011514344A (ja) 置換スルホンアミド誘導体
HK1132266B (en) Substituted sulfonamide derivatives

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100525

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100604

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130604

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130827

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131030

LAPS Cancellation because of no payment of annual fees